{
    "medicine_id": "ee31aa57a923b2a875ec338452aa132a10a803fb",
    "platform_id": "DB04904",
    "metadata": {
        "name": "Natrecor 1 5 mg 5mL Injection powder lyophilized for solution",
        "composition": "1 5 mg 5mL Amolimogene",
        "clinical_particulars": {
            "therapeutic_indications": "Intended for the treatment of cervical dysplasia associated with the human papillomavirus HPV",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Amolimogene was shown to be well tolerated in all patients and to promote the resolution of CIN 2 3 in women younger than 25 years",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}